|
2023 Journal Article Comparison of the effectiveness and safety of 2 aspirin doses in secondary prevention of cardiovascular outcomes in patients with chronic kidney disease: A subgroup analysis of ADAPTABLEGupta, Kamal, Mehta, Harsh, Kim, Hwasoon, Stebbins, Amanda, Wruck, Lisa M., Muñoz, Daniel, Effron, Mark B., Anderson, R. David, Pepine, Carl J., Jain, Sandeep K., Girotra, Saket, DeWalt, Darren A., Whittle, Jeff, Benziger, Catherine P., Farrehi, Peter, Zhou, Li, Knowlton, Kirk U., Polonsky, Tamar S., Bradley, Steven M., Harrington, Robert A., Rothman, Russell L., Jones, W. Schuyler and Hernandez, Adrian F. (2023). Comparison of the effectiveness and safety of 2 aspirin doses in secondary prevention of cardiovascular outcomes in patients with chronic kidney disease: A subgroup analysis of ADAPTABLE. American Heart Journal, 264, 31-39. doi: 10.1016/j.ahj.2023.06.001 |
|
2023 Journal Article Thrombotic risk in patients with acute coronary syndromes discharged on prasugrel or clopidogrel: results from the PROMETHEUS studyChiarito, Mauro, Cao, Davide, Sartori, Samantha, Zhang, Zhongjie, Vogel, Birgit, Spirito, Alessandro, Smith, Kenneth F., Weintraub, William, Strauss, Craig, Toma, Catalin, DeFranco, Anthony, Effron, Mark B., Stefanini, Giulio, Keller, Stuart, Kapadia, Samir, Rao, Sunil V., Henry, Timothy D., Pocock, Stuart, Sharma, Samin, Dangas, George, Kini, Annapoorna, Baber, Usman and Mehran, Roxana (2023). Thrombotic risk in patients with acute coronary syndromes discharged on prasugrel or clopidogrel: results from the PROMETHEUS study. European Heart Journal: Acute Cardiovascular Care, 12 (9), 594-603. doi: 10.1093/ehjacc/zuad083 |
|
2023 Journal Article Novel tissue factor inhibition for thromboprophylaxis in COVID-19: primary results of the ASPEN-COVID-19 TrialHess, Connie N., Hsia, Judith, Carroll, Ian A., Nehler, Mark R., Ruf, Wolfram, Morrow, David A., Nicolau, Jose C., Berwanger, Otavio, Szarek, Michael, Capell, Warren H., Johri, Shilpa, Pursley, Michael S., Gupta, Ryan, Meehan, Patrick S., Franchi, Francesco, Effron, Mark B., Marshall, Debra, Graybill, Christopher A., Graybill, Sophie P., Keuer, Thomas, Bristow, Michael R. and Bonaca, Marc P. (2023). Novel tissue factor inhibition for thromboprophylaxis in COVID-19: primary results of the ASPEN-COVID-19 Trial. Arteriosclerosis, Thrombosis, and Vascular Biology, 43 (8), 1572-1582. doi: 10.1161/atvbaha.122.318748 |
|
2023 Journal Article Internet versus noninternet participation in a decentralized clinical trial: lessons from the ADAPTABLE studyShen, Rebecca, Mulder, Hillary, Wruck, Lisa, Weissler, E. Hope, Robertson, Holly R., Sharlow, Amber G., Kripalani, Sunil, Muñoz, Daniel, Effron, Mark B., Gupta, Kamal, Girotra, Saket, Whittle, Jeff, Benziger, Catherine P., VanWormer, Jeffrey J., Polonsky, Tamar S., Rothman, Russell L., Harrington, Robert A., Hernandez, Adrian F. and Jones, W. Schuyler (2023). Internet versus noninternet participation in a decentralized clinical trial: lessons from the ADAPTABLE study. Journal of the American Heart Association, 12 (13) e027899, 1-18. doi: 10.1161/jaha.122.027899 |
|
2023 Journal Article Pragmatic evaluation of events and benefits of lipid lowering in older adults (PREVENTABLE): trial design and rationaleJoseph, Jacob, Pajewski, Nicholas M., Dolor, Rowena J., Sellers, Mary Ann, Perdue, Letitia H., Peeples, Sheronda R., Henrie, Adam M., Woolard, Nancy, Jones, W. Schuyler, Benziger, Catherine P., Orkaby, Ariela R., Mixon, Amanda S., VanWormer, Jeffrey J., Shapiro, Michael D., Kistler, Christine E., Polonsky, Tamar S., Chatterjee, Ranee, Chamberlain, Alanna M., Forman, Daniel E., Knowlton, Kirk U., Gill, Thomas M., Newby, L. Kristin, Hammill, Bradley G., Cicek, Mine S., Williams, Neely A., Decker, Jake E., Ou, Jiafu, Rubinstein, Jack, Choudhary, Gaurav ... Ramalingam, Ramesh (2023). Pragmatic evaluation of events and benefits of lipid lowering in older adults (PREVENTABLE): trial design and rationale. Journal of the American Geriatrics Society, 71 (6), 1701-1713. doi: 10.1111/jgs.18312 |
|
2022 Journal Article Racial disparities and excess cardiovascular mortality before and during the COVID-19 pandemic: time for a solutionObi, Koyenum and Effron, Mark B. (2022). Racial disparities and excess cardiovascular mortality before and during the COVID-19 pandemic: time for a solution. Mayo Clinic Proceedings, 97 (12), 2180-2183. doi: 10.1016/j.mayocp.2022.10.015 |
|
2022 Conference Publication Comparison of Enteric Coated Aspirin With Plain Aspirin on Effectiveness and Safety in the ADAPTABLE TrialEffron, Mark B., Sleem, Amber, Stebbins, Amanda, Wruck, Lisa M., Gravel, Guillaume, Munoz, Daniel, Re, Richard N., Gupta, Kamal, Pepine, Carl, Jain, Sandeep, Girotra, Saket, Whittle, Jeffrey, Benziger, Catherine, Farrehi, Peter M., Knowlton, Kirk U., Polonsky, Tamar S., Roe, Matthew T., Rothman, Russell T., Harrington, Robert A., Jones, William S. and Hernandez, Adrian F. (2022). Comparison of Enteric Coated Aspirin With Plain Aspirin on Effectiveness and Safety in the ADAPTABLE Trial. Scientific Sessions of the American-Heart-Association / Resuscitation Science Symposium, Chicago Il, Nov 05-06, 2022. PHILADELPHIA: LIPPINCOTT WILLIAMS & WILKINS. |
|
2022 Conference Publication Contribution of Clinical Trial Event Data by Data Source: Insights From the ADAPTABLE TrialRymer, Jennifer A., Mulder, Hillary, Wruck, Lisa M., Munoz, Daniel, Kripalani, Sunil, Effron, Mark B., Gupta, Kamal, Handberg, Eileen M., Jain, Sandeep, Girotra, Saket, Whittle, Jeffrey, Hess, Rachel, Benziger, Catherine, Knowlton, Kirk U., Curtis, Lesley, Roe, Matthew T., Hammill, Bradley G., Rothman, Russell, Harrington, Josephine, Hernandez, Adrian F. and Jones, William (2022). Contribution of Clinical Trial Event Data by Data Source: Insights From the ADAPTABLE Trial. Scientific Sessions of the American-Heart-Association / Resuscitation Science Symposium, Chicago Il, Nov 05-06, 2022. PHILADELPHIA: LIPPINCOTT WILLIAMS & WILKINS. |
|
2022 Conference Publication Patient Differences in Prescription Patterns for Proprotein Convertase Subtilisin/Kexin Type 9 Inhibitors When More Intensive Therapy is NeededEffron, Mark B., Kakkar, Anjali, Desrosiers, Greg, Velasco-Gonzalez, Cruz and Cooper-dehoff, Rhonda M. (2022). Patient Differences in Prescription Patterns for Proprotein Convertase Subtilisin/Kexin Type 9 Inhibitors When More Intensive Therapy is Needed. Scientific Sessions of the American-Heart-Association / Resuscitation Science Symposium, Chicago Il, Nov 05-06, 2022. PHILADELPHIA: LIPPINCOTT WILLIAMS & WILKINS. doi: 10.1161/circ.146.suppl_1.14224 |
|
2022 Conference Publication Effect of Aspirin Dosing in Patients Treated With P2Y12 Inhibitors for Secondary Prevention of Cardiovascular EventsGirotra, Saket, Stebbins, Amanda, Wruck, Lisa M., Riley, Danielle, Kripalani, Sunil, Munoz, Daniel, Effron, Mark B., Gupta, Kamal, Whittle, Jeffrey, Benziger, Catherine, Zhou, Li, Farrehi, Peter M., Polonsky, Tamar S., Ahmad, Faraz S., Roe, Matthew T., Rothman, Russell, Harrington, Robert A., Hernandez, Adrian F. and Jones, William S. (2022). Effect of Aspirin Dosing in Patients Treated With P2Y12 Inhibitors for Secondary Prevention of Cardiovascular Events. Scientific Sessions of the American-Heart-Association / Resuscitation Science Symposium, Chicago Il, Nov 05-06, 2022. PHILADELPHIA: LIPPINCOTT WILLIAMS & WILKINS. |
|
2022 Journal Article Importance of More Potent Antiplatelet Therapy in Myocardial Infarction With Cardiac Arrest or Cardiogenic ShockEffron, Mark B. (2022). Importance of More Potent Antiplatelet Therapy in Myocardial Infarction With Cardiac Arrest or Cardiogenic Shock. Mayo Clinic Proceedings, 97 (6), 1041-1043. doi: 10.1016/j.mayocp.2022.04.012 |
|
2022 Journal Article Proposal for a simple algorithmic approach to manage drug-drug interactions of oral anticoagulants with nirmatrelvir/ritonavir in COVID-19 outpatientsRizk, John G., Lazo, Jose G., Gupta, Aashish, Lavie, Carl J. and Effron, Mark B. (2022). Proposal for a simple algorithmic approach to manage drug-drug interactions of oral anticoagulants with nirmatrelvir/ritonavir in COVID-19 outpatients. Seminars in Thrombosis and Hemostasis, 49 (01), 085-088. doi: 10.1055/s-0042-1750024 |
|
2022 Journal Article To Anticoagulate or Not to Anticoagulate in COVID-19: Lessons after 2 YearsRizk, John G., Gupta, Aashish, Lazo, Jose G., Sardar, Partha, Henry, Brandon Michael, Lavie, Carl J. and Effron, Mark B. (2022). To Anticoagulate or Not to Anticoagulate in COVID-19: Lessons after 2 Years. Seminars in Thrombosis and Hemostasis, 49 (01), 062-072. doi: 10.1055/s-0042-1744302 |
|
2021 Journal Article Therapeutic anticoagulation with heparin in noncritically ill patients with covid-19Lawler, Patrick R., Goligher, Ewan C., Berger, Jeffrey S., Neal, Matthew D., McVerry, Bryan J., Nicolau, Jose C., Gong, Michelle N., Carrier, Marc, Rosenson, Robert S., Reynolds, Harmony R., Turgeon, Alexis F., Escobedo, Jorge, Huang, David T., Bradbury, Charlotte A., Houston, Brett L., Kornblith, Lucy Z., Kumar, Anand, Kahn, Susan R., Cushman, Mary, McQuilten, Zoe, Slutsky, Arthur S., Kim, Keri S., Gordon, Anthony C., Kirwan, Bridget-Anne, Brooks, Maria M., Higgins, Alisa M., Lewis, Roger J., Lorenzi, Elizabeth, Berry, Scott M. ... The ATTACC, ACTIV-4a, and REMAP-CAP Investigators (2021). Therapeutic anticoagulation with heparin in noncritically ill patients with covid-19. New England Journal of Medicine, 385 (9), 790-802. doi: 10.1056/NEJMoa2105911 |
|
2021 Journal Article Therapeutic anticoagulation with heparin in critically ill patients with covid-19Goligher, Ewan C., Bradbury, Charlotte A., McVerry, Bryan J., Lawler, Patrick R., Berger, Jeffrey S., Gong, Michelle N., Carrier, Marc, Reynolds, Harmony R., Kumar, Anand, Turgeon, Alexis F., Kornblith, Lucy Z., Kahn, Susan R., Marshall, John C., Kim, Keri S., Houston, Brett L., Derde, Lennie P.G., Cushman, Mary, Tritschler, Tobias, Angus, Derek C., Godoy, Lucas C., McQuilten, Zoe, Kirwan, Bridget-Anne, Farkouh, Michael E., Brooks, Maria M., Lewis, Roger J., Berry, Lindsay R., Lorenzi, Elizabeth, Gordon, Anthony C., Berry, Scott M. ... The REMAP-CAP, ACTIV-4a, and ATTACC Investigators (2021). Therapeutic anticoagulation with heparin in critically ill patients with covid-19. New England Journal of Medicine, 385 (9), 777-789. doi: 10.1056/NEJMoa2103417 |
|
2021 Journal Article Clinician engagement in the ADAPTABLE (Aspirin Dosing: A Patient-centric Trial Assessing Benefits and Long-Term Effectiveness) trialKochar, Ajar, Summers, Mary B., Benziger, Catherine P., Marquis-Gravel, Guillaume, DeWalt, Darren A., Pepine, Carl J., Gupta, Kamal, Bradley, Steven M., Dodson, John A., Lampert, Brent C., Robertson, Holly, Polonsky, Tamar S., Jones, W. Schuyler and Effron, Mark B (2021). Clinician engagement in the ADAPTABLE (Aspirin Dosing: A Patient-centric Trial Assessing Benefits and Long-Term Effectiveness) trial. Clinical Trials, 18 (4) 1740774520988838, 449-456. doi: 10.1177/1740774520988838 |
|
2021 Journal Article Comparative effectiveness of aspirin dosing in cardiovascular diseaseJones, W. Schuyler, Mulder, Hillary, Wruck, Lisa M., Pencina, Michael J., Kripalani, Sunil, Muñoz, Daniel, Crenshaw, David L., Effron, Mark B., Re, Richard N., Gupta, Kamal, David Anderson, R., Pepine, Carl J., Handberg, Eileen M., Manning, Brittney R., Jain, Sandeep K., Girotra, Saket, Riley, Danielle, DeWalt, Darren A., Whittle, Jeff, Goldberg, Ythan H., Roger, Veronique L., Hess, Rachel, Benziger, Catherine P., Farrehi, Peter, Zhou, Li, Ford, Daniel E., Haynes, Kevin, VanWormer, Jeffrey J., Knowlton, Kirk U. ... for the ADAPTABLE Team (2021). Comparative effectiveness of aspirin dosing in cardiovascular disease. New England Journal of Medicine, 384 (21), 1981-1990. doi: 10.1056/NEJMoa2102137 |
|
2020 Journal Article Prasugrel use and clinical outcomes by age among patients undergoing PCI for acute coronary syndrome: from the PROMETHEUS studyChandrasekhar, Jaya, Baber, Usman, Sartori, Samantha, Aquino, Melissa, Moalem, Kamilia, Kini, Annapoorna S., Rao, Sunil V., Weintraub, William, Henry, Timothy D., Vogel, Birgit, Ge, Zhen, Muhlestein, Joseph B., Weiss, Sandra, Strauss, Craig, Toma, Catalin, DeFranco, Anthony, Claessen, Bimmer E., Keller, Stuart, Baker, Brian A., Effron, Mark B., Pocock, Stuart, Dangas, George, Kapadia, Samir and Mehran, Roxana (2020). Prasugrel use and clinical outcomes by age among patients undergoing PCI for acute coronary syndrome: from the PROMETHEUS study. Clinical Research in Cardiology, 109 (6), 725-734. doi: 10.1007/s00392-019-01561-4 |
|
2020 Journal Article Incidence, predictors and impact of stroke on mortality among patients with acute coronary syndromes following percutaneous coronary intervention—Results from the PROMETHEUS registryChandiramani, Rishi, Chen, Huazhen, Aoi, Shunsuke, Giustino, Gennaro, Claessen, Bimmer, Sartori, Samantha, Aquino, Melissa, Sorrentino, Sabato, Cao, Davide, Goel, Ridhima, Kini, Annapoorna, Rao, Sunil, Weintraub, William, Henry, Timothy D., Kapadia, Samir, DeFranco, Anthony, Muhlestein, Joseph B., Toma, Catalin, Effron, Mark B., Keller, Stuart, Baker, Brian A., Pocock, Stuart, Baber, Usman and Mehran, Roxana (2020). Incidence, predictors and impact of stroke on mortality among patients with acute coronary syndromes following percutaneous coronary intervention—Results from the PROMETHEUS registry. Catheterization and Cardiovascular Interventions, 95 (5) ccd.28369, 885-892. doi: 10.1002/ccd.28369 |
|
2020 Journal Article Rationale and Design of the Aspirin Dosing-A Patient-Centric Trial Assessing Benefits and Long-term Effectiveness (ADAPTABLE) TrialMarquis-Gravel, Guillaume, Roe, Matthew T., Robertson, Holly R., Harrington, Robert A., Pencina, Michael J., Berdan, Lisa G., Hammill, Bradley G., Faulkner, Madelaine, Muñoz, Daniel, Fonarow, Gregg C., Nallamothu, Brahmajee K., Fintel, Dan J., Ford, Daniel E., Zhou, Li, Daugherty, Sarah E., Nauman, Elizabeth, Kraschnewski, Jennifer, Ahmad, Faraz S., Benziger, Catherine P., Haynes, Kevin, Merritt, J. Greg, Metkus, Thomas, Kripalani, Sunil, Gupta, Kamal, Shah, Raj C., McClay, James C., Re, Richard N., Geary, Carol, Lampert, Brent C. ... Jones, W. Schuyler (2020). Rationale and Design of the Aspirin Dosing-A Patient-Centric Trial Assessing Benefits and Long-term Effectiveness (ADAPTABLE) Trial. JAMA Cardiology, 5 (5) 0116, 598-607. doi: 10.1001/jamacardio.2020.0116 |
